West Pharmaceutical Services (WST) : Gw&k Investment Management scooped up 26,956 additional shares in West Pharmaceutical Services during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 19, 2016. The investment management firm now holds a total of 1,180,178 shares of West Pharmaceutical Services which is valued at $85,409,482.West Pharmaceutical Services makes up approximately 1.88% of Gw&k Investment Management’s portfolio.
West Pharmaceutical Services opened for trading at $71.55 and hit $72.51 on the upside on Friday, eventually ending the session at $72.37, with a gain of 0.84% or 0.6 points. The heightened volatility saw the trading volume jump to 3,09,137 shares. Company has a market cap of $5,235 M.
Other Hedge Funds, Including , Ami Asset Management Corp reduced its stake in WST by selling 19,019 shares or 8.01% in the most recent quarter. The Hedge Fund company now holds 218,282 shares of WST which is valued at $15,797,068. West Pharmaceutical Services makes up approx 1.06% of Ami Asset Management Corp’s portfolio.Fisher Asset Management reduced its stake in WST by selling 11,790 shares or 0.95% in the most recent quarter. The Hedge Fund company now holds 1,228,363 shares of WST which is valued at $88,896,630. West Pharmaceutical Services makes up approx 0.17% of Fisher Asset Management’s portfolio.Acadian Asset Management reduced its stake in WST by selling 24 shares or 52.17% in the most recent quarter. The Hedge Fund company now holds 22 shares of WST which is valued at $1,569.Independent Portfolio Consultants reduced its stake in WST by selling 220 shares or 2.41% in the most recent quarter. The Hedge Fund company now holds 8,905 shares of WST which is valued at $634,927. West Pharmaceutical Services makes up approx 0.18% of Independent Portfolio Consultants’s portfolio.
On the company’s financial health, West Pharmaceutical Services reported $0.47 EPS for the quarter, based on the information available during the earnings call on Feb 18, 2016. Analyst had a consensus estimate of $0.47. The company had revenue of $359.70 million for the quarter, compared to analysts expectations of $364.76 million. The company’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.45 EPS.
Many Wall Street Analysts have commented on West Pharmaceutical Services. West Pharmaceutical Services was Initiated by Wells Fargo to “Outperform” on Mar 22, 2016.
West Pharmaceutical Services Inc. is a manufacturer of components and systems for the packaging and delivery of injectable drugs as well as delivery system components for the pharmaceutical healthcare and consumer products industries. The Company’s products include stoppers and seals for vials prefillable syringe components and systems components for intravenous and blood collection systems safety and administration systems advanced injection systems and contract design and manufacturing services. The Company’s customers include producers of pharmaceuticals biologics medical devices and personal care products. The Company’s reportable segments include Pharmaceutical Packaging Systems segment (Packaging Systems) and the Pharmaceutical Delivery Systems segment (Delivery Systems).